Schmeiser T, Arnold R, Wiesneth M, Hertenstein B, Bunjes D, Anger B, Heit W, Heimpel H
Abteilung Innere Medizin III, Universität Ulm.
Dtsch Med Wochenschr. 1988 Jan 8;113(1):6-10. doi: 10.1055/s-2008-1067582.
Between April 1982 and December 1986, HLA-identical bone marrow transplantations were performed on 25 patients with Philadelphia chromosome-positive chronic myelocytic leukaemia (CML), 18 in the chronic phase, 7 in acceleration or blast crisis. Twelve of the 18 patients (67%) in the chronic phase are still alive a median period of 570 days after transplantation, but only two of the seven (29%) in acceleration or blast crisis a median period of 227 days after transplantation (P less than 0.025). The duration of the chronic phase was of great importance for survival after transplantation: 86% of patients in the chronic phase for less than two years survived, but all patients in the chronic phase for over two years died (P less than 0.001). CML relapses occurred in one patient in a late chronic phase and in two in an advanced stage of the disease. These results confirm the unfavorable outcome of bone marrow transplantation in the accelerated phase or blast crisis, as well as in the late chronic phase. Since at present there are no reliable risk factors for the occurrence of acceleration or blast crisis, bone marrow transplantation should be undertaken as early as possible in the chronic phase of CML.
1982年4月至1986年12月期间,对25例费城染色体阳性的慢性粒细胞白血病(CML)患者进行了 HLA 相同的骨髓移植,其中18例处于慢性期,7例处于加速期或急变期。18例慢性期患者中有12例(67%)在移植后中位时间570天仍存活,但7例加速期或急变期患者中只有2例(29%)在移植后中位时间227天仍存活(P<0.025)。慢性期的持续时间对移植后的生存至关重要:慢性期少于两年的患者中86%存活,但慢性期超过两年的所有患者均死亡(P<0.001)。1例处于慢性期晚期的患者和2例处于疾病晚期的患者发生了CML复发。这些结果证实了在加速期或急变期以及慢性期晚期进行骨髓移植的不良预后。由于目前尚无可靠的加速期或急变期发生风险因素,因此在CML慢性期应尽早进行骨髓移植。